Erasca
Tracked across 5 events · 30 articles · First seen May 19, 2026 · Last active Jun 12, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Regulatory
Robbins LLP has filed a class action lawsuit against Erasca, Inc. on behalf of investors who purchased its securities between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca made false and…
Impact: Erasca is the defendant in a class action lawsuit alleging misleading statements regarding its ERAS-0015 drug candidate, which led to a drop in its stock price. The company denies the allegations and intends to contest them.
Jun 11, 2026 · 6 articles
Regulatory
A class action lawsuit has been filed against Erasca>>> by Bragar Eagel & Squire>>> on behalf of stockholders who purchased common stock between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca>>>…
Impact: Erasca>>> is facing a class action lawsuit due to allegations of false and misleading statements regarding its ERAS-0015 drug, which led to a significant drop in its share price.
May 19, 2026 · 6 articles
Regulatory
Rosen Law Firm has announced a class action lawsuit against Erasca, Inc., its CEO, and CFO, alleging violations of federal securities laws. The lawsuit claims that Erasca made false and misleading statements about its oncology…
Impact: Erasca is the defendant in a class action lawsuit alleging securities fraud due to misleading statements about its oncology drug candidate, ERAS-0015. This event negatively impacts its stock price and reputation.
Jun 11, 2026 · 6 articles
Business
A class action lawsuit has been filed against Erasca, Inc. by Kirby McInerney LLP on behalf of investors who acquired Erasca securities between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca,…
Impact: Erasca is facing a class action lawsuit for allegedly making false and misleading statements about its drug candidate ERAS-0015, leading to a significant decline in its stock price. It is also accused of patent infringement and trade secret misappropriation by Revolution Medicines.
Jun 12, 2026 · 6 articles
Regulatory
The The Schall Law Firm has announced a class action lawsuit against Erasca, Inc. for alleged violations of the Securities Exchange Act of 1934 and Rule 10b-5. The lawsuit claims that Erasca made false and…
Impact: Erasca is the defendant in a class action lawsuit for allegedly making false and misleading statements regarding its preclinical data for ERAS-0015, leading to investor losses.
Jun 12, 2026 · 6 articles
100
Robbins LLP filed class action lawsuit ErascaErasca faces class action lawsuit
100
Bragar Eagel & Squire filed class action lawsuit ErascaErasca faces class action lawsuit
100
Rosen Law Firm announced class action lawsuit ErascaErasca securities fraud...
95
Erasca stock price fellErasca faces class action lawsuit
95
Erasca made false statementsErasca faces securities...
95
Erasca reported preliminary clinical dataErasca faces class action lawsuit
90
Erasca stock price fellErasca faces class action lawsuit
90
Erasca made false statementsErasca securities fraud...
90
Revolution Medicines sent letter alleging infringement ErascaErasca faces class action lawsuit
90
Revolution Medicines sent letter alleging infringement ErascaErasca faces class action lawsuit
90
Kirby McInerney LLP filed class action lawsuit ErascaErasca faces class action lawsuit
90
The Schall Law Firm reminded investors of lawsuit ErascaErasca faces securities...
85
Erasca disclosed letterErasca faces class action lawsuit
85
Erasca disclosed letter Revolution MedicinesErasca faces class action lawsuit
80
Erasca disclosed letterErasca faces class action lawsuit
80
Revolution Medicines sent letter alleging infringement ErascaErasca faces class action lawsuit
NEWSDESK
Track Erasca live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard